Expect Equity LLC’s Integra LifeSciences IART Stock Holding History

Expect Equity LLC’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-92,105	Closed	-$1.32M	–	61
2025 Q3	$1.32M	Hold	92,105	–	–	1.29%	39
2025 Q2	$1.13M	Hold	92,105	–	–	1.21%	38
2025 Q1	$2.03M	Hold	92,105	–	–	2.28%	23
2024 Q4	$2.09M	Buy	+92,105	New	+$2.01M	2.19%	24

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Expect Equity LLC's IART Position: Q4 2025 in Review

Expect Equity LLC sold out of Integra LifeSciences (IART) in Q4 2025, closing a stake of 92,105 shares — an estimated $1.32M sold.

Expect Equity LLC first reported a position in IART in Q4 2024 and held it in 4 quarters. The position peaked at $2.09M in Q4 2024. 204 funds tracked by Wall St. Rank hold IART as of Q4 2025.

Expect Equity LLC reported no remaining Integra LifeSciences position as of Q4 2025 after selling out during the quarter.
Expect Equity LLC sold 92,105 Integra LifeSciences shares in Q4 2025, an estimated $1.32M.
Expect Equity LLC first reported a position in Integra LifeSciences in Q4 2024 and held it in 4 quarters.
Expect Equity LLC's Integra LifeSciences position peaked at $2.09M in Q4 2024.
204 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2025.

Based on Expect Equity LLC's 13F filing for Q4 2025, filed 17 Feb 2026.